SI-BONE, Inc. (NASDAQ:SIBN) Receives Average Recommendation of “Buy” from Analysts

SI-BONE, Inc. (NASDAQ:SIBN) has received an average recommendation of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $23.00.

Several research analysts have weighed in on SIBN shares. Truist Financial increased their price target on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of SI-BONE in a research note on Monday, January 13th.

Insiders Place Their Bets

In related news, insider Anthony J. Recupero sold 3,937 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $12.60, for a total value of $49,606.20. Following the completion of the transaction, the insider now owns 228,554 shares of the company’s stock, valued at $2,879,780.40. The trade was a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Laura Francis sold 10,048 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the sale, the chief executive officer now owns 482,875 shares in the company, valued at $6,074,567.50. The trade was a 2.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,344 shares of company stock worth $357,292 in the last quarter. Corporate insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On SI-BONE

Hedge funds and other institutional investors have recently made changes to their positions in the company. Harbor Capital Advisors Inc. increased its stake in SI-BONE by 222.5% in the third quarter. Harbor Capital Advisors Inc. now owns 620,490 shares of the company’s stock valued at $8,674,000 after acquiring an additional 428,110 shares during the last quarter. Champlain Investment Partners LLC lifted its stake in SI-BONE by 14.7% during the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock worth $39,145,000 after purchasing an additional 358,821 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of SI-BONE by 11.0% in the 4th quarter. American Century Companies Inc. now owns 2,378,068 shares of the company’s stock valued at $33,341,000 after purchasing an additional 236,167 shares in the last quarter. Impax Asset Management Group plc increased its stake in shares of SI-BONE by 41.3% in the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock valued at $10,604,000 after purchasing an additional 221,604 shares during the last quarter. Finally, First Eagle Investment Management LLC acquired a new position in shares of SI-BONE during the 4th quarter worth $2,600,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SI-BONE Stock Down 2.2 %

NASDAQ:SIBN opened at $16.22 on Thursday. The firm’s fifty day moving average price is $15.15 and its two-hundred day moving average price is $14.53. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. SI-BONE has a one year low of $11.70 and a one year high of $21.19.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.